Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L. Ferris, Maura L. Gillison, Kevin J. Harrington et al.|New England Journal of Medicine|2016Cited by 5.1k
Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.Robert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|Journal of Clinical Oncology|2016Cited by 53
Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141Maura L. Gillison, Robert L. Ferris, George R. Blumenschein et al.|Cancer Research|2016Cited by 36